Rice Hall James & Associates LLC lessened its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 23.5% during the 4th quarter, HoldingsChannel.com reports. The fund owned 181,255 shares of the company’s stock after selling 55,752 shares during the period. Rice Hall James & Associates LLC’s holdings in Pacira BioSciences were worth $4,691,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. grew its position in Pacira BioSciences by 5,900.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock valued at $39,000 after acquiring an additional 1,475 shares during the last quarter. Kestra Advisory Services LLC bought a new position in Pacira BioSciences in the 4th quarter valued at $48,000. Eurizon Capital SGR S.p.A. bought a new position in Pacira BioSciences in the 4th quarter valued at $51,000. Global Retirement Partners LLC grew its position in Pacira BioSciences by 479.4% in the 4th quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock valued at $52,000 after acquiring an additional 1,678 shares during the last quarter. Finally, Hantz Financial Services Inc. grew its position in shares of Pacira BioSciences by 127.3% during the 4th quarter. Hantz Financial Services Inc. now owns 2,573 shares of the company’s stock worth $67,000 after buying an additional 1,441 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.
Pacira BioSciences Price Performance
PCRX opened at $22.74 on Tuesday. Pacira BioSciences, Inc. has a 12-month low of $18.80 and a 12-month high of $27.64. The company has a current ratio of 4.73, a quick ratio of 3.35 and a debt-to-equity ratio of 0.56. The business’s fifty day simple moving average is $23.58 and its 200-day simple moving average is $23.27. The company has a market capitalization of $894.82 million, a price-to-earnings ratio of 189.52 and a beta of 0.29.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on the company. Needham & Company LLC increased their price target on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Zacks Research raised Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Royal Bank Of Canada increased their price target on Pacira BioSciences from $22.00 to $24.00 and gave the stock a “sector perform” rating in a research report on Friday, May 1st. Wall Street Zen downgraded Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Barclays dropped their price target on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 26th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $29.40.
Check Out Our Latest Research Report on PCRX
Insiders Place Their Bets
In related news, CFO Shawn Cross sold 12,941 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $25.16, for a total transaction of $325,595.56. Following the completion of the sale, the chief financial officer directly owned 105,341 shares in the company, valued at $2,650,379.56. This represents a 10.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Lauren Riker sold 6,115 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $23.50, for a total value of $143,702.50. Following the sale, the senior vice president owned 62,284 shares of the company’s stock, valued at $1,463,674. This trade represents a 8.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 31,115 shares of company stock valued at $771,896 over the last 90 days. 6.40% of the stock is currently owned by company insiders.
Pacira BioSciences Company Profile
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.
In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.
Featured Articles
- Five stocks we like better than Pacira BioSciences
- Father’s Day Investing: 3 Stocks Built for Long-Term Returns
- This Golden Cross Could Send Urban Outfitters to New Highs
- Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold?
- Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report).
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
